-

12:42:26 PM

ACRS Stock News

ACRS - Aclaris Therapeutics Inc

09/20/23 7:00 AM

Nasdaq : ACRS

conferences

Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a

RHEA-AI

neutral

09/18/23 7:00 AM

Nasdaq : ACRS

clinical trial

Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for

RHEA-AI

neutral

08/07/23 7:00 AM

Nasdaq : ACRS

earnings

Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel

RHEA-AI

neutral

06/13/23 7:01 AM

Nasdaq : ACRS

clinical trial

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the completion of enrollment into

RHEA-AI

neutral

06/02/23 7:00 AM

Nasdaq : ACRS

conferences

Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in two

RHEA-AI

neutral

05/08/23 7:00 AM

Nasdaq : ACRS

earnings

Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial

RHEA-AI

neutral

05/02/23 7:01 AM

Nasdaq : ACRS

earnings

Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced it will report financial results for the first quarter 2023 on Monday,

RHEA-AI

neutral

03/27/23 7:00 AM

Nasdaq : ACRS

conferences

Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a

RHEA-AI

neutral

03/06/23 7:00 AM

Nasdaq : ACRS

clinical trial

Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis Suppurativa

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a

RHEA-AI

negative

02/23/23 7:00 AM

Nasdaq : ACRS

earnings

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2022 and

RHEA-AI

neutral

1 2 3 4 5 6 Next

ACRS Data

IndustryPharmaceutical Preparation Manufacturing
Websitehttps://www.aclaristx.com/
Security nameAclaris Therapeutics Inc
SectorManufacturing
Tags
- Health Technology
- Pharmaceuticals: Other
- Manufacturing
- Pharmaceutical Preparation Manufacturing
CountryUS

About Aclaris Therapeutics Inc

aclaris therapeutics, inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. aclaris is focused on market segments with no fda-approved medications or where treatment gaps exist. aclaris was founded by dermatologists and is led by a team with extensive experience in developing and commercializing dermatologic treatments.